Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as directors.
Knight joins as a Class I director, serving through to the company’s 2028 annual meeting, and will also sit on the audit and risk committee. Denaro returns to the board as a Class II director with a term running until the 2026 annual meeting.
The pair come in just as Anteris has enrolled and successfully treated the first US patients in the global pivotal trial of its DurAVR® transcatheter heart valve (THV) for severe calcific aortic stenosis. The first US procedures were performed by Dr Azeem Latib at Montefiore Medical Center in New York.
Knight brings medical device and finance expertise
Knight most recently chaired the board of medical device company Surmodics Inc, a role she held from 2015 until November 2025. She has more than 15 years of listed company board experience and extensive audit committee expertise, including chair roles at Surmodics, Greater Metropolitan Housing Corporation and Plato Learning.
Her executive career includes serving as senior vice president and chief financial officer of MTS Systems Corporation from 2011 to 2014, after holding the CFO role there for a decade.
Before joining MTS, Knight spent 24 years with Honeywell Inc, including as vice president of finance for its Home and Building Control business.
Anteris said Knight’s background across medical devices, governance and financial management would support the company as it progresses development and commercialisation activities.
Denaro returns with deep company knowledge
Denaro rejoins the board bringing detailed knowledge of Anteris and its strategic priorities.
In addition to his board role, he continues to serve as company secretary for several of Anteris’ Australian subsidiary entities, for which he receives an annual fee of A$57,645.
The company said there were no arrangements or relationships requiring disclosure in connection with either appointment.
Director remuneration outlined
As non-executive directors, Knight and Denaro will receive annual cash retainers under Anteris’ non-employee director compensation policy.
Knight will also receive an initial restricted stock unit (RSU) grant valued at US$250,000, vesting over three years subject to continued board service and shareholder approval under ASX listing rules.
Both directors will also be eligible for annual RSU grants valued at US$125,000, subject to ongoing board service.
Anteris confirmed it had entered indemnification agreements with both directors effective May 11, 2026, under arrangements previously disclosed in its US regulatory filings.